$RGBP
Regen BioPharma Inc Stock $rgbp

$rgbp Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000160706223000215 Filed on April 18, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$31.64K	$58.37K
YoY Change	-45.79%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$101.5K	$70.50K
YoY Change	43.91%	-16.73%
% of Gross Profit
Research & Development	$36.45K	$64.37K
YoY Change	-43.38%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$36.45K	$134.9K
YoY Change	-72.97%	56.27%
Operating Profit	-$78.84K	-$76.49K
YoY Change	3.07%
Interest Expense	$12.09K	-$66.71M
YoY Change	-100.02%	-3217.06%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$300.0K
YoY Change	-100.0%
Pretax Income	-$54.98K	-$67.08M
YoY Change	-99.92%	-3281.41%
Income Tax
% Of Pretax Income
Net Earnings	-$54.98K	-$67.08M
YoY Change	-99.92%	-15270.55%
Net Earnings / Revenue	-173.76%	-114924.77%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.03	-$14.70K
COMMON SHARES
Basic Shares Outstanding	5.048B shares	3.043M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$87.70K	$234.7K
YoY Change	-62.63%
Cash & Equivalents	$87.70K	$234.7K
Short-Term Investments
Other Short-Term Assets	$17.23K	$34.58K
YoY Change	-50.17%
Inventory
Prepaid Expenses	$7.233K
Receivables	$79.12K	$268.0K
Other Receivables	$0.00	$5.890K
Total Short-Term Assets	$184.1K	$543.2K
YoY Change	-66.12%	243.68%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$222.6K	$87.68K
YoY Change	153.85%	339.06%
Other Assets
YoY Change
Total Long-Term Assets	$222.6K	$87.68K
YoY Change	153.85%	339.06%
TOTAL ASSETS
Total Short-Term Assets	$184.1K	$543.2K
Total Long-Term Assets	$222.6K	$87.68K
Total Assets	$406.6K	$630.9K
YoY Change	-35.54%	254.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$34.05K	$41.63K
YoY Change	-18.22%	-64.46%
Accrued Expenses	$1.616M	$1.977M
YoY Change	-18.28%	-12.62%
Deferred Revenue
YoY Change
Short-Term Debt	$101.7K	$1.230K
YoY Change	8169.11%	-98.05%
Long-Term Debt Due	$509.9K	$2.997M
YoY Change	-82.99%	20.69%
Total Short-Term Liabilities	$5.336M	$77.38M
YoY Change	-93.1%	1374.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.336M	$77.38M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$5.336M	$77.38M
YoY Change	-93.1%	1374.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.32M
YoY Change
Common Stock	$339.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.930M	-$76.75M
YoY Change
Total Liabilities & Shareholders Equity	$406.6K	$630.9K
YoY Change	-35.54%	254.38%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$54.98K	-$67.08M
YoY Change	-99.92%	-15270.55%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$53.04K	-$118.8K
YoY Change	-55.36%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities		$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	100.0K	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-53.04K	-118.8K
Cash From Investing Activities		0.000
Cash From Financing Activities	100.0K	0.000
Net Change In Cash	46.96K	-118.8K
YoY Change	-139.53%
FREE CASH FLOW
Cash From Operating Activities	-$53.04K	-$118.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001589150
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	RGBP	Common Shares Issued For Debt CommonSharesIssuedForDebt		usd
	us-gaap	Interest Paid InterestPaid		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-191725
	dei	Entity Registrant Name EntityRegistrantName	REGEN BIOPHARMA, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5192997
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4700 Spring Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	St 304
	dei	Entity Address City Or Town EntityAddressCityOrTown	La Mesa
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91942
	dei	City Area Code CityAreaCode	619
	dei	Local Phone Number LocalPhoneNumber	722-5505
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3381366	shares
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	us-gaap	Cash Cash	87700	usd
CY2022Q3	us-gaap	Cash Cash	51204	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	79123	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	254273	usd
CY2022Q3	RGBP	Notes Receivable Related Party Current NotesReceivableRelatedPartyCurrent	0	usd
CY2022Q3	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	0	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7233	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	20945	usd
CY2023Q1	us-gaap	Prepaid Rent PrepaidRent	10000	usd
CY2022Q3	us-gaap	Prepaid Rent PrepaidRent	10000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	184055	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	336422	usd
CY2022Q3	RGBP	Available For Sale Securitie AvailableForSaleSecuritie	0	usd
CY2023Q1	RGBP	Investment Securities Related Party InvestmentSecuritiesRelatedParty	222580	usd
CY2022Q3	RGBP	Investment Securities Related Party InvestmentSecuritiesRelatedParty	222580	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	222580	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	222580	usd
CY2023Q1	us-gaap	Assets Assets	406635	usd
CY2022Q3	us-gaap	Assets Assets	559002	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	34047	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	28799	usd
CY2023Q1	us-gaap	Notes And Loans Payable NotesAndLoansPayable	100710	usd
CY2022Q3	us-gaap	Notes And Loans Payable NotesAndLoansPayable	710	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4241	usd
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4241	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	313448	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	689785	usd
CY2023Q1	RGBP	Accrued Rent AccruedRent	0	usd
CY2022Q3	RGBP	Accrued Rent AccruedRent	0	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1256630	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1266679	usd
CY2023Q1	RGBP	Other Accrued Expenses OtherAccruedExpenses	41423	usd
CY2022Q3	RGBP	Other Accrued Expenses OtherAccruedExpenses	41423	usd
CY2023Q1	us-gaap	Bank Overdrafts BankOverdrafts	1000	usd
CY2022Q3	us-gaap	Bank Overdrafts BankOverdrafts	1000	usd
CY2023Q1	RGBP	Due To Investor DueToInvestor	20000	usd
CY2022Q3	RGBP	Due To Investor DueToInvestor	20000	usd
CY2023Q1	RGBP	Unearned Income UnearnedIncome	1655010	usd
CY2022Q3	RGBP	Unearned Income UnearnedIncome	1718290	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	1400000	usd
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	3551793	usd
CY2023Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	499880	usd
CY2022Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1262340	usd
CY2023Q1	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount	10000	usd
CY2022Q3	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount	10000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5336389	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8595061	usd
CY2023Q1	us-gaap	Liabilities Liabilities	5336389	usd
CY2022Q3	us-gaap	Liabilities Liabilities	8595061	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3354866	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3381366	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	339	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	503150	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13658153	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11581499	usd
CY2023Q1	us-gaap	Other Additional Capital OtherAdditionalCapital	736326	usd
CY2022Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	736326	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19324617	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20905369	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4929755	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8036059	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	406635	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	559002	usd
CY2023Q1	us-gaap	Revenues Revenues	31640	usd
CY2022Q1	us-gaap	Revenues Revenues	30945	usd
	us-gaap	Revenues Revenues	63280	usd
	us-gaap	Revenues Revenues	62584	usd
CY2023Q1	RGBP	Revenues Related Party RevenuesRelatedParty	27425	usd
CY2022Q1	RGBP	Revenues Related Party RevenuesRelatedParty	27425	usd
	RGBP	Revenues Related Party RevenuesRelatedParty	54849	usd
	RGBP	Revenues Related Party RevenuesRelatedParty	54849	usd
CY2023Q1	RGBP	Total Revenues TotalRevenues	59065	usd
CY2022Q1	RGBP	Total Revenues TotalRevenues	58369	usd
	RGBP	Total Revenues TotalRevenues	118129	usd
	RGBP	Total Revenues TotalRevenues	117434	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36446	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27390	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	131959	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62809	usd
CY2023Q1	RGBP	Research And Development Related Party ResearchAndDevelopmentRelatedParty	0	usd
CY2022Q1	RGBP	Research And Development Related Party ResearchAndDevelopmentRelatedParty	36975	usd
	RGBP	Research And Development Related Party ResearchAndDevelopmentRelatedParty	0	usd
	RGBP	Research And Development Related Party ResearchAndDevelopmentRelatedParty	117250	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18660	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5355	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27398	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12013	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	67800	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	50143	usd
	us-gaap	Professional Fees ProfessionalFees	471480	usd
	us-gaap	Professional Fees ProfessionalFees	88279	usd
CY2023Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	15000	usd
CY2022Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	15000	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	30000	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	20000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	137906	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	134863	usd
	us-gaap	Costs And Expenses CostsAndExpenses	660837	usd
	us-gaap	Costs And Expenses CostsAndExpenses	300351	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-78842	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-76494	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-542708	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-182917	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	131	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	266	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	12085	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	42561	usd
	us-gaap	Interest Expense InterestExpense	29444	usd
	us-gaap	Interest Expense InterestExpense	77571	usd
CY2022Q1	RGBP	Interest Expense Attributable To Amortization Of Discount InterestExpenseAttributableToAmortizationOfDiscount	-21977	usd
	RGBP	Interest Expense Attributable To Amortization Of Discount InterestExpenseAttributableToAmortizationOfDiscount	-44428	usd
CY2022Q1	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	300000	usd
	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	300000	usd
CY2022Q1	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	-6405	usd
	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	-130296	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	usd
CY2022Q1	RGBP	Gain Loss On Derecognition Of Accounts Payable GainLossOnDerecognitionOfAccountsPayable	0	usd
	RGBP	Gain Loss On Derecognition Of Accounts Payable GainLossOnDerecognitionOfAccountsPayable	62700	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	35949	usd
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-66634282	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2151755	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-63699343	usd
CY2022Q1	RGBP	Financing Fees FinancingFees	0	usd
CY2022Q1	RGBP	Legal Settlement LegalSettlement	0	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1150	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-95019	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	23864	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-67005095	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2123460	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-64253692	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-54978	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-67081589	usd
	us-gaap	Net Income Loss NetIncomeLoss	1580752	usd
	us-gaap	Net Income Loss NetIncomeLoss	-64436609	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-54978	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67081589	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1391061	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-64436609	usd
CY2023Q1	RGBP	Basic And Fully Diluted Earnings Loss Per Share BasicAndFullyDilutedEarningsLossPerShare	-0.0332
CY2022Q1	RGBP	Basic And Fully Diluted Earnings Loss Per Share BasicAndFullyDilutedEarningsLossPerShare	-22.04
	RGBP	Basic And Fully Diluted Earnings Loss Per Share BasicAndFullyDilutedEarningsLossPerShare	0.41
	RGBP	Basic And Fully Diluted Earnings Loss Per Share BasicAndFullyDilutedEarningsLossPerShare	-21.31
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1656429	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3043028	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3364578	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3023724	shares
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-13485877	usd
CY2021Q4	RGBP	Shares Issued For Debt Amount SharesIssuedForDebtAmount	100000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value SharesIssuedForInterestValue	26662	usd
CY2021Q4	RGBP	Shares Issued For Debt1 Amount SharesIssuedForDebt1Amount	100000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value1 SharesIssuedForInterestValue1	38837	usd
CY2021Q4	RGBP	Shares Issued For Debt2 Amount SharesIssuedForDebt2Amount	50000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value2 SharesIssuedForInterestValue2	19603	usd
CY2021Q4	RGBP	Shares Issued For Debt3 Amount SharesIssuedForDebt3Amount	50000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value3 SharesIssuedForInterestValue3	18575	usd
CY2021Q4	RGBP	Shares Issued For Interest Value4 SharesIssuedForInterestValue4	75000	usd
CY2021Q4	RGBP	Shares Issued For Debt4 Amount SharesIssuedForDebt4Amount	32075	usd
CY2021Q4	RGBP	Shares Issued For Interest Value5 SharesIssuedForInterestValue5	25000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value6 SharesIssuedForInterestValue6	10356	usd
CY2021Q4	RGBP	Shares Issued For Debt5 Amount SharesIssuedForDebt5Amount	25000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value7 SharesIssuedForInterestValue7	8883	usd
CY2021Q4	RGBP	Shares Issued For Debt6 Amount SharesIssuedForDebt6Amount	50000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value8 SharesIssuedForInterestValue8	23369	usd
CY2021Q4	RGBP	Shares Issued For Debt7 Amount SharesIssuedForDebt7Amount	100000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value9 SharesIssuedForInterestValue9	39808	usd
CY2021Q4	RGBP	Shares Issued For Debt8 Amount SharesIssuedForDebt8Amount	40000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value10 SharesIssuedForInterestValue10	14192	usd
CY2021Q4	RGBP	Shares Issued For Debt9 Amount SharesIssuedForDebt9Amount	50000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value11 SharesIssuedForInterestValue11	19012	usd
CY2021Q4	RGBP	Shares Issued For Debt10 Amount SharesIssuedForDebt10Amount	10964	usd
CY2021Q4	RGBP	Shares Issued For Debt11 Amount SharesIssuedForDebt11Amount	25000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value12 SharesIssuedForInterestValue12	11527	usd
CY2021Q4	RGBP	Shares Issued For Debt12 Amount SharesIssuedForDebt12Amount	60000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value13 SharesIssuedForInterestValue13	25440	usd
CY2021Q4	RGBP	Shares Issued For Debt13 Amount SharesIssuedForDebt13Amount	25000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value14 SharesIssuedForInterestValue14	10625	usd
CY2021Q4	us-gaap	Profit Loss ProfitLoss	2644980	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9755969	usd
CY2022Q1	RGBP	Shares Issued For Debt Amount SharesIssuedForDebtAmount	48420	usd
CY2022Q1	RGBP	Shares Issued For Interest Value SharesIssuedForInterestValue	39708	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-67081589	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-76749430	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-8036059	usd
CY2022Q4	RGBP	Preferred Shares Issued For Nonemployee Services PreferredSharesIssuedForNonemployeeServices	300000	usd
CY2022Q4	RGBP	Preferred Shares Issued For Debt PreferredSharesIssuedForDebt	761500	usd
CY2022Q4	RGBP	Preferred Shares Issued For Interest PreferredSharesIssuedForInterest	380262	usd
CY2022Q4	RGBP	Common Shares Issued For Interest CommonSharesIssuedForInterest	25369	usd
CY2022Q4	RGBP	Preferred Shares Issued For Nonemployee Services1 PreferredSharesIssuedForNonemployeeServices1	48372	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	1635730	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4884827	usd
CY2023Q1	RGBP	Reverse Stock Split Value ReverseStockSplitValue	0	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10050	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-54978	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4929755	usd
	us-gaap	Net Income Loss NetIncomeLoss	1580752	usd
	us-gaap	Net Income Loss NetIncomeLoss	-64436609	usd
	RGBP	Preferred Stock Issued As Compensation PreferredStockIssuedAsCompensation	-348372	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	44428	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5248	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-49870	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-175150	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	54850	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	29444	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	48597	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-13714	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-13652	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-2151755	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	63699343	usd
	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-63280	usd
	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-62585	usd
	RGBP	Increase Decrease In Penalties IncreaseDecreaseInPenalties	300000	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	266	usd
	RGBP	Gain Loss On Forgiveness Of Debt GainLossOnForgivenessOfDebt	1150	usd
	RGBP	Unrealized Lossgain On Investment Securities UnrealizedLossgainOnInvestmentSecurities	-130296	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63504	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-397953	usd
	RGBP	Increase Decrease In Convertible Notes Payable IncreaseDecreaseInConvertibleNotesPayable	-94535	usd
	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	100000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-94535	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	36496	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-492488	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51204	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	727162	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87700	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	234674	usd
	RGBP	Common Shares Issued For Debt CommonSharesIssuedForDebt	759384	usd
	RGBP	Preferred Share Issued For Debt PreferredShareIssuedForDebt	761500	usd
	RGBP	Preferred Share Issued For Debt PreferredShareIssuedForDebt	75000	usd
	us-gaap	Interest Paid InterestPaid	28973	usd
	RGBP	Common Shares Issued For Interests CommonSharesIssuedForInterests	25369	usd
	RGBP	Common Shares Issued For Interests CommonSharesIssuedForInterests	304678	usd
	RGBP	Preferred Shares Issued For Interests PreferredSharesIssuedForInterests	380262	usd
	RGBP	Preferred Shares Issued For Interests PreferredSharesIssuedForInterests	33994	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0348	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	8.9505	pure
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
	us-gaap	Advertising Expense AdvertisingExpense	0	usd
	RGBP	Net Income Loss Since Inception NetIncomeLossSinceInception	19324617	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3381366	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 1500

Files In Submission

Name	View Source	Status
0001607062-23-000215-index-headers.html	Edgar Link	pending
0001607062-23-000215-index.html	Edgar Link	pending
0001607062-23-000215.txt	Edgar Link	pending
0001607062-23-000215-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgbp-20230331.xsd	Edgar Link	pending
rgbp033123form10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rgbp-20230331_cal.xml	Edgar Link	unprocessable
rgbp-20230331_def.xml	Edgar Link	unprocessable
rgbp-20230331_pre.xml	Edgar Link	unprocessable
rgbp-20230331_lab.xml	Edgar Link	unprocessable
rgbp033123form10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGBP
Regen BioPharma Inc Stock $rgbp

2023 Q1 Form 10-Q Financial Statement

#000160706223000215 Filed on April 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGBP Regen BioPharma Inc Stock $rgbp

2023 Q1 Form 10-Q Financial Statement

#000160706223000215 Filed on April 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGBP
Regen BioPharma Inc Stock $rgbp